Intellia Therapeutics, Inc. (NTLA)

Intellia Therapeutics, Inc. (NTLA) Healthcare & Pipeline Overview

Intellia Therapeutics, Inc. pioneers CRISPR/Cas9-based therapeutics, targeting genetic diseases and cancer with both in vivo and ex vivo programs. Their innovative approach positions them in the competitive biotechnology sector, marked by strategic collaborations and a focus on novel genomic medicines.

What Is the Investment Thesis for NTLA?

Intellia Therapeutics presents a high-risk, high-reward investment opportunity within the rapidly evolving field of gene editing. The company's lead programs, NTLA-2001 and NTLA-2002, are in Phase 1 clinical trials, representing significant milestones but also carrying substantial clinical and regulatory risk. Successful clinical trial outcomes and subsequent regulatory approvals could drive significant value appreciation. Key value drivers include the expansion of the CRISPR/Cas9 platform to new therapeutic areas and the strength of its strategic partnerships with Novartis and Regeneron. The company's high beta of 1.99 suggests significant volatility. A profit margin of -609.9% and a gross margin of -25.6% reflect the substantial R&D expenses typical of early-stage biotech companies. Upcoming data readouts from ongoing clinical trials are key catalysts. Potential risks include clinical trial failures, regulatory hurdles, and competition from other gene editing companies.

Based on FMP financials and quantitative analysis

NTLA Key Highlights

• NTLA-2001 is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis (ATTR), showcasing progress in in vivo gene editing.
• NTLA-2002 is in development for the treatment of hereditary angioedema (HAE), expanding the application of Intellia's CRISPR/Cas9 technology.
• Strategic collaborations with Novartis and Regeneron provide financial resources and expertise to accelerate drug development.
• The company's ex vivo pipeline includes NTLA-5001 for acute myeloid leukemia, demonstrating a focus on oncology applications.
• Intellia's CRISPR/Cas9 system offers tools for gene editing, contributing to revenue generation and market presence.

Who Are NTLA's Competitors?

NTLA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NTLA's Key Strengths?

• Proprietary CRISPR/Cas9 technology platform
• Strong pipeline of in vivo and ex vivo programs
• Strategic collaborations with Novartis and Regeneron
• Experienced management team

What Are NTLA's Weaknesses?

• Early-stage clinical development with high risk of failure
• High R&D expenses and negative profit margins
• Reliance on collaborations for funding and expertise
• Limited commercialization experience

What Could Drive NTLA Stock Higher?

• Data readouts from Phase 1 clinical trial of NTLA-2001 for transthyretin amyloidosis.
• Data readouts from Phase 1 clinical trial of NTLA-2002 for hereditary angioedema.
• Progress in preclinical development of liver-focused programs for hemophilia A and B.
• Advancement of ex vivo pipeline, including NTLA-5001 for acute myeloid leukemia.
• Expansion of strategic collaborations with pharmaceutical companies.

What Are the Key Risks for NTLA?

• Negative return on equity (-57.3%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for lead programs.
• Regulatory delays or rejection of marketing applications.
• Competition from other gene editing companies.
• Patent disputes and intellectual property challenges.
• High R&D expenses and negative profit margins.

What Are the Growth Opportunities for NTLA?

• Expansion of In Vivo Programs: Intellia has the opportunity to expand its in vivo programs beyond NTLA-2001 and NTLA-2002. The company is targeting liver-focused programs for hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Success in these programs could address large patient populations with significant unmet medical needs. The market for hemophilia A treatment alone is projected to reach $15 billion by 2028. Intellia's CRISPR/Cas9 technology offers the potential for one-time curative treatments, providing a competitive advantage over existing therapies.
• Advancement of Ex Vivo Pipeline: Intellia's ex vivo pipeline, including NTLA-5001 for acute myeloid leukemia, represents another significant growth opportunity. Engineered cell therapies are gaining traction in oncology, with the potential to provide personalized and effective treatments. The market for cell therapies is expected to reach $50 billion by 2030. Intellia's expertise in CRISPR/Cas9 technology positions it to develop novel cell therapies with improved efficacy and safety profiles.
• Strategic Collaborations: Intellia's collaborations with Novartis, Regeneron, and other partners provide access to resources, expertise, and new therapeutic targets. These collaborations can accelerate drug development and expand the company's pipeline. For example, the collaboration with Regeneron focuses on co-developing potential products for hemophilia A and B. Successful collaborations can generate revenue through milestone payments and royalties, contributing to long-term growth.
• Development of Next-Generation CRISPR Technologies: Intellia is investing in the development of next-generation CRISPR technologies to improve the precision, efficiency, and safety of gene editing. These advancements can expand the applicability of CRISPR/Cas9 to a wider range of diseases and reduce the risk of off-target effects. The market for advanced gene editing tools is expected to grow rapidly, driven by the increasing demand for precise and safe gene editing therapies. Intellia's innovation in this area can provide a competitive edge.
• Geographic Expansion: Intellia has the opportunity to expand its geographic presence beyond the United States and Europe. Emerging markets, such as Asia and Latin America, represent significant growth opportunities due to their large populations and increasing healthcare spending. Establishing partnerships and conducting clinical trials in these regions can accelerate the adoption of Intellia's therapies and generate new revenue streams. However, navigating regulatory and market access challenges in these regions will be crucial for success.

What Opportunities Does NTLA Have?

• Expansion of CRISPR/Cas9 technology to new therapeutic areas
• Advancement of pipeline programs through clinical trials
• Strategic acquisitions and partnerships
• Geographic expansion into emerging markets

What Threats Does NTLA Face?

• Competition from other gene editing companies
• Regulatory hurdles and delays
• Clinical trial failures
• Patent disputes and intellectual property challenges

What Are NTLA's Competitive Advantages?

• Proprietary CRISPR/Cas9 technology platform.
• Strong intellectual property portfolio.
• Strategic collaborations with leading pharmaceutical companies.
• Expertise in both in vivo and ex vivo gene editing approaches.

What Does NTLA Do?

Intellia Therapeutics, Inc., founded in 2014 and headquartered in Cambridge, Massachusetts, is a biotechnology company focused on developing curative therapeutics using CRISPR/Cas9 technology. The company's origins lie in the promise of revolutionizing medicine through precise genome editing. Intellia's research and development efforts are divided into in vivo and ex vivo programs. The in vivo programs involve directly editing genes within the patient's body, with lead candidates including NTLA-2001 for transthyretin amyloidosis (ATTR) and NTLA-2002 for hereditary angioedema (HAE). Other liver-focused programs target hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. The ex vivo pipeline focuses on engineering cells outside the body before transplanting them back into the patient. NTLA-5001 is being developed for acute myeloid leukemia, and other proprietary programs are focused on engineered cell therapies for oncological and autoimmune disorders. Intellia also provides CRISPR/Cas9 systems for research purposes. The company has established collaborations with Novartis, Regeneron Pharmaceuticals, Ospedale San Raffaele, and SparingVision SAS to expand its research and development capabilities and broaden the application of its technology. These collaborations focus on areas such as sickle cell disease, hemophilia, and ocular diseases, reflecting Intellia's commitment to addressing a wide range of unmet medical needs.

What Products and Services Does NTLA Offer?

• Develops therapeutics using CRISPR/Cas9 gene editing technology.
• Focuses on both in vivo and ex vivo gene editing approaches.
• Targets genetic diseases such as transthyretin amyloidosis and hereditary angioedema.
• Develops engineered cell therapies for oncological and autoimmune disorders.
• Offers CRISPR/Cas9 systems for research purposes.
• Collaborates with pharmaceutical companies to expand research and development efforts.
• Conducts clinical trials to evaluate the safety and efficacy of its therapies.

How Does NTLA Make Money?

• Develops and commercializes gene editing therapeutics.
• Generates revenue through licensing agreements and collaborations.
• Receives milestone payments and royalties from partnered programs.
• Potentially generates revenue from direct sales of CRISPR/Cas9 systems for research.

What Industry Does NTLA Operate In?

Intellia Therapeutics operates in the rapidly growing biotechnology industry, specifically within the gene editing sector. The market for gene editing technologies is projected to reach billions of dollars by 2030, driven by advancements in CRISPR/Cas9 and other gene editing tools. The competitive landscape includes companies like SYRE: Spyre Therapeutics, Inc., which are also developing novel therapies for various diseases. Intellia's focus on both in vivo and ex vivo approaches differentiates it from some competitors. The industry is characterized by high R&D costs, long development timelines, and significant regulatory hurdles.

Who Are NTLA's Key Customers?

• Patients with genetic diseases and cancer.
• Pharmaceutical companies through licensing and collaboration agreements.
• Research institutions and scientists using CRISPR/Cas9 systems.

ROE -57%Key Financial Metrics

Return on equity for Intellia Therapeutics, Inc. stands at -57.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -52.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -18.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.10 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -19.2%, the inverse of the P/E and a quick read on earnings relative to price.

How Intellia Therapeutics, Inc. Is Valued

Intellia Therapeutics, Inc. carries a market capitalization of $2.00B, placing it in the mid-cap category. Relative to its peer group, NTLA's quantitative score of 19/100 is below the peer average of 78/100.

F-Score 3/9Financial Health

Intellia Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 2.61 places it in the grey zone, a middle ground that warrants monitoring.

FY2026 estForward Outlook

Wall Street analysts project Intellia Therapeutics, Inc. revenue of about $59.0M for fiscal 2026, with EPS near $-3.22. The estimate reflects 15 contributing analysts.

Net buyingInsider Activity

Over the past six months, Intellia Therapeutics, Inc. insiders filed 15 SEC Form 4 transactions — 0 sales and 15 purchases. On net that is roughly 314K shares acquired (about $1.2M) — insiders putting money in tends to read as conviction.

NTLA Financials

NTLA Latest News

NTLA Analyst Consensus

NTLA MoonshotScore

Latest Intellia Therapeutics, Inc. Analysis

Related Investment Themes

What Investors Ask About Intellia Therapeutics, Inc. (NTLA) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources